GSK plc (GSK) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 18/100
- 10Y CAGR
- 2.2%
- Median YoY
- 4.2%
- YoY volatility
- σ 9.6pp· smooth
- Quarters ≥ 20%
- 0 of 40
- Negative quarters
- 11
- Valuation vs own 10Y history
- P/S 2.4x · 10Y median 2.0x · 98th percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 0 of 40 → 0 of 40 pts
- Steadiness (typical swing 9.6pp) → 18.1 of 25 pts
- Pace (median 4.2% YoY) → 0 of 20 pts
- Latest quarter (1.7% YoY) → 0 of 15 pts
- Score: 18 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 2.2% | 4.2% | 9.6pp | 0 of 40 | 11 |
| EPSEPS | -5.1% | 12.8% | 129.4pp | 14 of 33 | 13 |
| Op cash flowOperating cash flow | 9.8% | 6.6% | 363.4pp | 15 of 40 | 16 |
| EBITDAEBITDA | -2% | 3.8% | 524.8pp | 17 of 40 | 19 |
| FCFFree cash flow | 23.1% | 7.6% | 523.5pp | 14 of 35 | 15 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: GSK on the compounders surface · All compounders, ranked